(Q44764447)

English

A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction

scientific article published in February 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 December 2017

A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction (English)

1 reference

Europe PubMed Central

6 December 2017

1 reference

based on heuristic

inferred from title

Anastasios Athanasopoulos

7

1 reference

Europe PubMed Central

6 December 2017

author name string

Perimenis P

1

1 reference

Europe PubMed Central

6 December 2017

Gyftopoulos K

2

1 reference

Europe PubMed Central

6 December 2017

Giannitsas K

3

1 reference

Europe PubMed Central

6 December 2017

Markou SA

4

1 reference

Europe PubMed Central

6 December 2017

Tsota I

5

1 reference

Europe PubMed Central

6 December 2017

Chrysanthopoulou A

6

1 reference

Europe PubMed Central

6 December 2017

Barbalias G

8

1 reference

Europe PubMed Central

6 December 2017

publication date

1 February 2004

1 reference

Europe PubMed Central

6 December 2017

International Journal of Impotence Research

1 reference

Europe PubMed Central

6 December 2017

16

1 reference

Europe PubMed Central

6 December 2017

1

1 reference

Europe PubMed Central

6 December 2017

2-7

1 reference

Europe PubMed Central

6 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.ijir.3901119

0 references

Impotence and aging: clinical and hormonal factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Treatment of erectile dysfunction with sildenafil.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Efficacy of apomorphine SL in erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

The efficacy of sildenafil citrate (Viagra) in clinical populations: an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Prognostic factors for response to sildenafil in patients with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Outcome Analysis of Goal Directed Therapy for Impotence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Mode of action of a new oral treatment for erectile dysfunction: apomorphine SL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Guidelines on erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Safety and tolerability of apomorphine SL (Uprima).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

A 4-year update on the safety of sildenafil citrate (Viagra).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

21 January 2018

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

7 January 2021

based on heuristic

inferred from DOI database lookup

Cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculogenic erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

7 January 2021

based on heuristic

inferred from DOI database lookup

Vasculogenic impotence evaluated by high-resolution ultrasonography and pulsed Doppler spectrum analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

7 January 2021

based on heuristic

inferred from DOI database lookup

Repetition of color Doppler ultrasonography: is it necessary?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901119

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.IJIR.3901119

1 reference

Europe PubMed Central

6 December 2017

1 reference

Europe PubMed Central

6 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44764447&oldid=2039466739"